LAUSR

subsequent 1 reactions during desensitization trials with rituximab using 12- , 16- and 20- step protocols. desensitization after the first omalizumab dose of 300 mg before 1 week of RDD. 13 Ojaimi et al achieved desensitization to carboplatin after the third omalizumab dose administered every two weeks. 14 Oude et al 15 administered a dose of omalizumab two weeks before carboplatin RDD without adverse events. In previous studies, omalizumab dosing in allergic asthma was based on patient weight and total IgE. In our case, we administered 6 doses of omalizumab (150 mg/dose) every two weeks before desensitization and contin-ued treatment once a month until completion of rituximab therapy. In patients with successful RDD on omalizumab, RDD steps can be reduced on subsequent infusions. Arroaberran et al. 16 presented a patient who tolerated elosulfase alpha enzyme without desensitization after omalizumab treatment. Desensitization may not be nec-essary after treatment with omalizumab. However, because of our patient's previous severe reaction, we preferred to be on the safe side and did not administer the entire dose directly. Data on omalizumab before RDD are very limited, and only in the aspirin desensitization study did patients receive RDD only after omalizumab was discontinued. 11 In conclusion, omalizumab may facilitate drug desensitization and allow continuation of preferred treatment. Further controlled studies of omalizumab treatment protocols in RDD are needed.